The strategic management of mergers and acquisitions in the pharmaceutical industry: Developing a resource-based perspective

Technology Analysis and Strategic Management

Volumn 14, Issue 3, 2002, Pages 299-313

  James, Andrew D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MERGER; PHARMACEUTICAL INDUSTRY; STRATEGIC APPROACH;

EID: 0036724537     PISSN: 09537325     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953732022000002122     Document Type: Article

References (54)

1. Knowledge and capabilities- A new view of the firm
2. The dominant logic: A new linkage between diversity and performance
3. A resource-based view of the firm
4. Firm resources and sustained competitive advantage
5. Stock accumulation and sustainability of competitive advantage
6. Strategic assets and organizational rent
7. The dynamic capabilities of firms: An introduction
8. Corporate decision-making on the sourcing of technological knowledge
9. Introduction: Towards the theory and practice of competence-based competition
10. Distributed capabilities and the governance of the firm
11. The resource-based theory of competitive advantage: Implications for strategy formulation
12. Asset redeployment, acquisitions and corporate strategy in declining industries
13. Resource redeployment following horizontal acquisitions in Europe and North America, 1988-1992
14. Bilateral resource redeployment and capabilities improvement following horizontal acquisitions
15. The long-term performance of horizontal acquisitions
16. Path-dependent and path-breaking change: Reconfiguring business resources following acquisitions in the US medical sector, 1978-1995
17. Asset divestiture following horizontal acquisitions: A dynamic view
18. Resource complementarity in business combinations: Extending the logic to organizational alliances
19. After the acquisition: Continuing challenge
20. When cultures collide: The anatomy of a merger
21. Organizational fit and acquisition performance: Effects of post-acquisition integration
22. Corporate acquisitions: A process perspective
23. Acquisitions: The process can be a problem
24. Integrating technology into merger and acquisition decision making
25. Organizational learning and a firm's core competence
26. Why do firms differ, and how does it matter?
27. Strategic management and the exploration of diversity
28. The pharmaceutical industry, 2000
29. Drug giants that are much too addicted to mergers
30. The painful path from hostility to synergy
31. Glaxo wellcome: Creating the world's largest drug company
32. GlaxoSmithKline- A merger of equals?
33. How Fred Hassan rescued pharmacia and upjohn
34. New management brings pharmacia and upjohn back from the brink
35. The mergers- Miracles, madness or mayhem?
36. Aventis, at last: Richard Markham, CEO, aventis pharma
37. R and D times two
38. Drug industry mergers won't necessarily benefit RandD
39. Marriages made in heaven?
40. Scale, scope and spillovers: The determinants of research productivity in drug discovery
41. The billion dollar pyramid: Megamergers' greatest challenge
42. Crafting strategy
43. Determinants of acquisition integration level: A decision-making perspective
44. Path(ological) dependency? Core competencies from an organizational perspective